Intraocular pressure (IOP)-lowering ophthalmic solutions that inhibit Rho-associated protein kinases (Rock) and norepinephrine transporters (Net) are currently under clinical evaluation. Here we evaluate topical application of one such drug for its effects on retinal ganglion cell (RGC) survival and axon regeneration after optic nerve crush injury. We performed unilateral optic nerve crush on young rats (P18) and topically applied Rock/Net inhibitor AR-13324 or placebo 3 times a day for 14 days. IOP was measured starting 3 days before and up to 9 days after injury. On day 12, cholera toxin B (CTB) was injected intravitreally to trace optic nerve regeneration. On day 14, retinas and optic nerves were collected. The retinas were flat-mounted and stained with RBPMS to quantify RGC survival and the optic nerves were sectioned for optic nerve axon quantification using fluorescent and confocal microscopy. Rock phosphorylation targets implicated in axon growth including cofilin and LIMK were examined by fluorescence microscopy and quantitative western blotting. AR-13324 lowered IOP as expected. RGC survival and optic nerve axon regeneration were significantly higher with Rock/Net inhibitor treatment compared with placebo. Furthermore, topical therapy decreased Rock target protein phosphorylation in the retinas and proximal optic nerves. These data suggest that topical administration of a Rock/Net inhibitor promotes RGC survival and regeneration after optic nerve injury, with associated molecular changes indicative of posterior drug activity. Coordinated IOP lowering and neuroprotective or regenerative effects may be advantageous in the treatment of patients with glaucoma.
Introduction
Failure of retinal ganglion cells (RGCs) to survive and regenerate their axons through the optic nerve underlies the permanent loss of vision in optic neuropathies such as glaucoma. Intraocular pressure lowering can slow the disease, but the search for effective therapies to protect and promote the growth of RGCs remains an important approach. Rho-associated protein kinases (Rocks) are AGC-family (PKA/PKG/PKC) serine-threonine kinases that regulate the shape and movement of cells by acting on the cytoskeleton (Maekawa et al., 1999; Riento and Ridley, 2003; Sanka et al., 2007; Wang et al., 2009) . Rho GTPases and Rocks contribute to regenerative failure, and Rock inhibition has been shown to promote axon regeneration in the central nervous system (CNS). (Kubo et al., 2007; Tan et al., 2011) .
In recent years, Rock inhibitors have emerged as a novel topical therapy to treat glaucoma by lowering intraocular pressures (IOP) through modulation of trabecular meshwork (TM) cells' actin cytoskeleton, resulting in increasing conventional outflow, the main route of aqueous humor outflow in human eyes (Challa and Arnold, 2014; Nakajima et al., 2005; Rao et al., 2001 Rao et al., , 2005 Wang and Chang, 2014) . In addition, Rock inhibitors have been reported to increase ocular blood flow to the optic nerve head, enhancing RGC survival and axon regeneration after ischemic injury (Sugiyama et al., 2011; Tokushige et al., 2011) . Rock inhibitors also reduce scar formation and inflammation following glaucoma filtering surgery. (Honjo et al., 2007) These data suggest that Rock inhibitors may have additional beneficial effects for the management of glaucoma other than reduction of IOP (Challa and Arnold, 2014; Wang and Chang, 2014; Yamamoto et al., 2014) .
Like Rock inhibitors, the norepinephrine transporter (Net) inhibitor has been shown to reduce IOP in animals including rabbits and monkeys (Bacharach et al., 2015; Wang et al., 2015) . By combining the IOP reducing effects of both Rock and Net inhibitors, Aerie pharmaceuticals developed a novel IOP-lowering ophthalmic solution AR-13324. Previous studies have demonstrated that AR-13324 reduces IOP in normotensive monkey eyes when applied topically (Wang et al., 2015) . However, the effect of topical AR-13324 on promoting RGC survival and axon regeneration has not been tested. In this report, we investigated whether topical Rock/Net inhibitor AR-13324 protects RGCs or promotes their axon regeneration following optic nerve injury, and probed potential mechanisms by examining known molecular targets of Rock's kinase activity in the retina and optic nerve.
Materials and methods

Animals
All procedures involving animals were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by Institutional Biosafety Committee and the Institutional Animal Care and Use Committee at the University of California, San Diego. Wild type male and female postnatal day 18 (P18) Sprague-Dawley rats (Harlan Laboratories, Placentia, CA, USA) were used for optic nerve crush. For counting and statistical analysis of retinas and optic nerve axons, a minimum of three and up to six rats of either sex were in each group, which prior analysis indicated would give a power of 0.8 to detect a 20% difference in survival at the p ¼ 0.05 level. All surgical procedures on rats were performed under general anesthesia using an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (7.5 mg/kg). Rats also received subcutaneous injection of buprenorphine (0.05 mg/kg; Bedford Laboratories, Bedford, OH, USA) as postoperative analgesic. Eye ointment containing erythromycin was applied to protect the cornea.
Topical administration of AR-13324
Rock/Net inhibitor (0.06% AR-13324) ophthalmic solution and the placebo vehicle solution with same formulation were topically applied by eye dropping. Fifteen microliters of each solution were applied three times a day for 14 consecutive days immediately after injury.
Intraocular pressure (IOP) measurement
Intraocular pressure (IOP) was measured using a TonoLab tonometer (iCare, Finland) under isoflurane anesthesia. Each eye was measured 10 times per session; reported results reflect the average of these 10 measurements. The baseline IOP was determined by measuring IOP once a day for three consecutive days before any surgical or topical therapeutic application. After optic nerve injury and topical application of the Rock/Net inhibitor or placebo, we measured IOP once a day 3, 6 and 9 days postsurgery.
Optic nerve crush and quantification of regenerating axons
Unilateral optic nerve crush was performed on young adult (P18) Sprague-Dawley rats. The animal was anesthetized, and an incision was made just behind the left eye. The optic nerve was exposed and the sheath opened longitudinally. The nerve was crushed 1 mm behind the eye with number 5 forceps for 5 s, avoiding injury to the ophthalmic artery. Nerve injury was verified visually at the crush site, and the vascular integrity to the retina was evaluated by funduscopic examination. After suturing the incision, the ophthalmic formulated Rock/Net inhibitor (0.06% AR-13324, Aerie Pharmaceuticals, Bedminster, NJ, USA) was topically administered on both injured and the fellow, noninjured eye three times a day for 14 consecutive days. Twelve days after the initial injury, Alexa Fluor 488-labeled cholera toxin B (CTB-488; 10 mg/ml; Invitrogen, Carlsbad, CA, USA) was injected intravitreally with care to avoid damaging the lens. Two days later, 14 days after injury, animals were deeply anesthetized and perfused with 4% PFA in 0.1 M phosphate buffer. Optic nerves were dissected and postfixed in 4% PFA for 1 h and subsequently washed in PBS. Optic nerves were incubated in 30% sucrose at 4 C overnight before mounting in optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA) for longitudinal 10-mm sectioning using a Leica cryostat (Buffalo Grove, IL, USA). The nerve sections were imaged with a 10Â objective using a Zeiss LSM510 confocal microscope. To quantify regenerating axons, we identified the crush site and determined the number of axons that crossed 250 mm increment distances from the crush as well as the length of the longest regenerating axon. All data were collected and analyzed by masked examiners.
Immunofluorescence staining and survival quantification of RGCs
Retinas were removed from the post-fixed eye and flatmounted. After wash with PBS, each retina was placed into a single well on a 24-well culture plate. Retinas were blocked and permeabilized in 10% normal goat serum and 0.2% Triton X-100 for 1 h, then incubated in the same medium with the antibody against the RNA Binding Protein with Multiple Splicing (RBPMS) (Thermo Fisher Scientific Inc., Rockford, IL USA), the RGC-specific marker, (1:500) overnight at 4 C. After washing 4 times with PBS, retinas were incubated with Alex 488-conjugated goat antiemouse secondary antibody (1:400; Invitrogen) overnight at 4 C. Retinas were then washed 4 times with PBS and flatmounted with the RGC layer uppermost. Each field sampled from central, middle and peripheral zones of 4 retinal leaflets (1.6 Â 1.6 mm per field, 12 fields per retina) was imaged and numbers of RGCs were counted in a masked fashion.
Western blot analysis
Retinas were lysed with lysis buffer (Cell Signaling Technology, Boston, MA, USA) containing 0.5 mM of phenylmethanesulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined by BCA protein assay (Thermo Fisher Scientific). Samples (25 mg) were separated by SDS-PAGE in 4e20% gradient Tris-glycine precast gels (Invitrogen) and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). The membrane was incubated for 1 h in blocking solution containing 5% non-fat milk powder and 0.1% Tween-20, pH 7.6. This was followed by overnight incubation at 4 C in the blocking buffer containing rabbit primary antibodies against cofilin, phospho-cofilin, and phospho-LIMK (all from Cell Signing Technology). Subsequently, the labeled proteins were visualized by incubation with a horseradish peroxidase (HRP)-conjugated anti-goat or rabbit IgG (1:2000; Santa Cruz Biotechnology) followed by development with a chemiluminescence substrate for HRP (Thermo Scientific). The images of western blots were captured by GE imageQuant. Relative band intensities were analyzed using Image J software and normalized to non-phospho-blots and to GAPDH.
Immunohistochemistry of retinal and optic nerve cross-sections
After cardiac perfusion with 4% paraformaldehyde, whole eyes from P21 rats were isolated, the corneas were cut open and the retinas were transferred to phosphate buffered saline (PBS) containing 4% paraformaldehyde for 1 h at room temperature, followed by 10% sucrose in PBS and finally, 30% sucrose in PBS. Retinas were then mounted in OCT, frozen and cryosectioned at 5 mm thickness. Three sections with an interval of 50 mm were acquired from each eye across the optic nerve to ensure centration. The same fixing and slicing procedures were applied for optic nerve sections. Cryosections were rinsed with PBS and blocked with 5% goat serum albumin (Gibco, Grand Island, NY, USA) and 0.2% Triton X-100 (Sigma-Aldrich) in antibody buffer for 1 h. Tissue was then incubated in antibody buffer containing the primary antibody for 24 h at 4 C. Sections were then rinsed in PBS and incubated in a fluorescent secondary antibody containing 4',6-diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, OR, USA) for 24 h at 4 C for nuclei staining. After three washes in PBS, these sections were mounted with Vectashield H1000 (Vector Laboratories, Burlingame, CA, USA) and photographed with a Leica microscope. Two secondary antibodies diluted 1:500 were used, Alexa 488 mouse anti-rabbit, or Alexa 546 goat anti-mouse (Molecular Probes).
Statistical analysis
Statistical analysis was performed using statistical software (Excel, Microsoft). RGC numbers from different groups were analyzed by Student's t-test for paired data. Data are presented as mean ± standard deviation with a minimum of n ¼ 3 animals per condition.
Results
Topical administration of Rock/Net inhibitor reduces IOP independent of optic nerve injury
To investigate whether the topical administration of Rock/Net inhibitor AR-13324 ophthalmic solution influences IOP following unilateral optic nerve crush in young adult rats, we recorded the IOP measurements once a day for three consecutive days as the baseline value before optic nerve crush. Following injury, AR-13324 or placebo was applied three times daily to both injured and non-injured fellow eyes. IOP was then measured on day 3, 6 and 9 after ONC and AR-13324 or placebo treatment. We found that optic nerve injury resulted in increased IOP in both the injured (Fig. 1A) and the fellow eyes (Fig. 1B) . However, daily topical application of AR-13324 ophthalmic solution significantly reduced IOP compared with placebo independent from the injury-related IOP increase (Fig. 1) . When we analyzed of the effect of AR-13324 on IOP regardless of injury, the decrease of IOP after 3 days 3 and of treatment was significant (P < 0.05). Thus, topical AR-13324 had its expected effect on IOP, confirming drug delivery and potency.
Effect on RGC survival following optic nerve injury
We quantified RBPMS þ immunostained RGCs in three regions of the retina, central, middle and periphery ( Fig. 2A) . Majority of RGCs died by 14 days following optic nerve crush (Fig. 2BeG) , as expected. Treatment with topical AR-13324 significantly increased RGC survival compared with placebo, in all 3 regions central, middle and peripheral (Fig. 2HeK) . Thus topical AR-13324 showed neuroprotective effects in this rat model of optic nerve injury.
Effect of AR-13324 on axon regeneration
We next tested whether topical application of AR-13324 could promote axon regeneration in vivo. Using cholera toxin subunit B (CTB) anterograde labeling to quantify axons at 2 weeks, we observed more regenerating axons in the treatment group compared with placebo controls (Fig. 3AeB) . We then measured the numbers of CTB-labeled axons in the optic nerve every 250 mm from the crush site to 5000 mm. The number of regenerating axons at 2 weeks after injury was significantly greater after treatment with topical AR-13324 (Fig. 3C) . At distances close to the injury site, regenerating axons numbered almost five times as many in the Rock/Net inhibitor-treated rats compared with placebo-treated rats; at longer distances (3000e4000 mm), this differential reduced but was still twice as many in the Rock/ Net inhibitor-treated rats (Fig. 3C) . No axon labeling was detected past the optic chiasm, confirming that this was not an effect on axon sparing, which would preserve intact axon labeling all the way to targets in the brain. Together, these data demonstrate that topical application of a Rock/Net inhibitor promotes regeneration of axons in vivo.
Effect of topical treatment on downstream Rock signaling targets
To examine whether topical application of a Rock/Net inhibitor affects target protein phosphorylation in the posterior eye, we obtained the retinas and optic nerves from uninjured rats after three days of consecutive application of AR-13324 or placebo on both eyes. We chose this early time point to study molecular effects at an early time point in uninjured animals, corresponding to the period before RGC death in optic nerve crush animals. Western blot analysis revealed that the phosphorylation of one key signaling target of Rock, cofilin, was significantly reduced in both the retinas and optic nerves (P < 0.05) (Fig. 4AeD) . A second downstream target of Rock, LIM kinase (LIMK), also demonstrated reduced phosphorylation after AR-13324 topical application compared with placebo treatment (Fig. 4EeF) .
Immunohistochemistry staining using anti-phospho-cofilin also showed that the phosphorylation of cofilin in RGCs and inner retinal cells was almost completely inhibited after AR-13324 treatment compared with placebo (Fig. 5) . We also examined whether topical rock inhibitor can affect its downstream molecular targets in the optic nerveby immunofluorescent staining for phospho-cofilin. AR-13324 decreased the detection of phosphocofilin in the proximal optic nerve, but this inhibition declined towards the optic chiasm (Fig. 6) . Because of the apparent distribution of phospho-cofilin in the optic nerve, we hypothesized its primary expression was in astrocytes. Immunofluorescence revealed p-cofilin in optic nerve cells that colocalized with GFAP (Fig. 7) , supporting this hypothesis. Thus topical Rock inhibition leads to loss of phosphorylation of Rock targets in RGCs and proximal optic nerve glial cells.
Discussion
The mainstay of glaucoma therapy is IOP-lowering medications or surgeries. Topical application of Rock inhibitor ophthalmic solutions has been shown to reduce IOP in many animal models including rats, rabbits (Waki et al., 2001) , (Nishio et al., 2009 ) and monkeys (Tokushige et al., 2007) , as well as in humans (Bacharach et al., 2015) . Both isoforms of Rock, Rock1 and Rock2, are expressed in the TM and in the ciliary body. When RhoA and Rock activity are high in TM cells, they act on actin stress fibers resulting in changes in cell shape, contractility and aqueous outflow (Zhang et al., 2008) . Inhibition of Rock activity relaxes cell tension, enhancing outflow facility through the TM and reducing IOP (Nakajima et al., 2005) . Thus, Rock inhibitors are under active investigation as IOP-lowering agents for glaucoma.
One such IOP-reducing ophthalmic drug, AR-13324, combines inhibitory activity against Rock1 and Rock2 with inhibitory activity against norepinephrine transporter (Net). AR-13324 has been shown to reduce IOP in rabbits and monkeys (Tokushige et al., 2007) . In this study, we found that optic nerve crush slightly increased IOP on both crushed and fellow eyes, averaging a rise from 8 to 14 mmHg, but importantly not to levels associated with RGC death. Interestingly, the fellow eyes of crush injury rats also displayed IOP increases but to a slightly lesser degree. The reason and underlying mechanisms associated with the IOP increases is an interesting question of its own and is not addressable in scope of Fig. 4 . Western blot quantitative analysis of Rock target protein phosphorylation. A,C,E show representative images of western blots against total cofilin, phospho-cofilin, GAPDH and phospho-LIMK in the retina or optic nerve obtained from non-injury rats treated with placebo or AR-13324 for three consecutive days as marked. B, D, F show quantification of the relative phospho-protein expression normalized to total protein and GAPDH as marked (N ¼ 3 for each biological sample; mean ± SEM; P values are indicated on the top of bars).
the current study, but may due to physiologic mechanisms responsive to stress, for example. In any case, IOP was significantly decreased by topical application of AR-13324 compared with eyes treated with placebo in either eye.
Besides modulation of IOP at the TM, much evidence has indicated the important role of Rho/Rock signaling in neuroprotection and axon regeneration. Mechanistic insight into Rock inhibitor in neuroprotection is still largely under investigation. Rho itself is a GTPase that plays an important role in axon growth and guidance by controlling the assembly and dynamic rearrangement of actin and microtubule cytoskeleton (Hall and Lalli, 2010) . In addition, Rho GTPase signaling plays an important function in regulating neuronal survival and death through negatively regulating pro-survival proteins such as Akt (-Stankiewicz and Linseman, 2014) . Downstream components of the Rock pathway are also highly expressed in the CNS and can negatively regulate neuron survival as well as axon outgrowth and guidance (Schmandke et al., 2007) resulting in axon retraction and growth cone collapse during development and axon regeneration (Gallo, 2006; Tonges et al., 2011) . For example, a particular class of ROCK downstream targets-the microtubuleassociated proteins (MAPs), such as Tau and MAP-2, play a major role in neurite extension by altering microtubule dynamics (Amano et al., 2003) . More recently, Rock-mediated phosphorylation of phosphatase and tensin homolog (PTEN) was shown to negatively regulate neuronal survival and axonal regeneration via the PIP3/Akt/mTOR pathway (Li et al., 2005 (Li et al., , 2011 Tonges et al., 2011) .
Importantly, inhibiting Rho/Rock signaling in RGCs or optic nerve can promote RGC survival and regeneration in optic nerve injury models when the inhibitor is delivered posteriorly, through soluble molecule or gene delivery directly to RGCs (Bertrand et al., 2005; Koch et al., 2014; McKerracher et al., 2012) . Whether the topical application of Rock inhibitors could provide a similar positive effect was previously unknown. In this study, we found that topical application of AR-13324 effectively reduces RGC death and promotes axonal regeneration in optic nerve following optic nerve injury. The premise that topical drug delivery penetrates to RGCs and the proximal optic nerve was further supported by immunofluorescence and western blotting against cofilin and other downstream mediators of Rock pathway signaling. cofilin is an actin binding protein that can be activated through dephosphorylation resulting in neuronal dysfunction and degeneration (Marsick et al., 2010) . cofilin localizes to the growth cone and is important for axon guidance (Marsick et al., 2010; Piper et al., 2006) . When bound to F-actin, cofilin changes the conformation of actin filaments, from a twisting structure to a severing filament (McGough et al., 1997) . In addition, cofilin enhances the dissociation rate of monomers at the pointed end of actin filaments resulting in their depolymerisation (Carlier et al., 1997; Ghosh et al., 2004) . However, such activity of cofilin was negatively regulated by phosphorylation mediated by LIM kinase (Yang et al., 1998; Yuen et al., 2011) . Prior work showed that Rock inhibition induced cofilin dephosphorylation and neurite outgrowth in cultured cells (Lingor et al., 2007; Zhang et al., 2006) . Our results demonstrated that after 3 days of topical AR-13324, cofilin was significantly dephosphorylated in both retina and optic nerve, consistent with the protective effect on RGC survival and promotion of axon regeneration. More interestingly, the dephosphorylation effect of AR-13324 on cofilin was stronger in the proximal optic nerve than in the optic chiasm, suggesting a decline in drug penetration and consistent with the decrease in distal regeneration. The localization of p-cofilin in optic nerve astrocytes demonstrated here suggests that some of the locus of activity of AR-13324 in promoting axon regeneration may actually be through Rock inhibition in optic nerve glia, not just in RGCs. Traumatic injury upregulates RhoA expression in neurons and glial cells in the spinal cord (Kang et al., 2013) . Specific inhibition of Rho signaling in RGCs promotes regeneration; (Bertrand et al., 2005 (Bertrand et al., , 2007 (Tan et al., 2012) , future experiments could be designed to explore specific inhibition of Rho signaling in optic nerve glia after injury, as well as to investigate the pharmacokinetic distribution and pharmacodynamic effects of ROCK inhibitors.
In summary, our study supports Rock inhibition as a very appealing therapeutic approach not only in lowering IOP but also in neuroprotection and axonal regeneration. Among considerations for future studies, it will be important to examine if similar effects are detected in older animals, consistent with older average ages of glaucoma patients; in less acute models consistent with the chronic nature of most open-angle glaucomas; and in species with greater resistance to posterior drug penetration than that observed in rodents, such as rabbit, pig or non-human primate, consistent with that observed in humans. Additionally, a more detailed analysis of the bioavailability of topical drug to the back of the eye, and doseresponse should be considered in future studies. With these caveats for future study in mind, the neuroprotective and axon regenerative potential of AR-13324 and other Rock inhibitors may be of significant importance in neuroprotective/regenerative strategies, in addition to lowering IOP, for glaucoma therapy.
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